Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences reported a first quarter 2026 net loss of $23.5M, similar to a $23.9M loss a year earlier, as it continues investing in its endocrine and metabolic pipeline. Cash, cash equivalents and marketable securities were $440.0M as of March 31, 2026, which the company expects will fund operations into 2029.
R&D expenses fell to $18.5M while G&A expenses rose to $8.8M, reflecting both lower trial costs and ongoing infrastructure build-out. MBX highlighted progress for once-weekly canvuparatide in hypoparathyroidism, including planned Phase 3 initiation in Q3 2026, expansion of its obesity portfolio around MBX 4291 and new candidates, and Phase 2 advancement of imapextide for post-bariatric hypoglycemia.
MBX Biosciences reported a first quarter 2026 net loss of $23.5M, similar to a $23.9M loss a year earlier, as it continues investing in its endocrine and metabolic pipeline. Cash, cash equivalents and marketable securities were $440.0M as of March 31, 2026, which the company expects will fund operations into 2029.
R&D expenses fell to $18.5M while G&A expenses rose to $8.8M, reflecting both lower trial costs and ongoing infrastructure build-out. MBX highlighted progress for once-weekly canvuparatide in hypoparathyroidism, including planned Phase 3 initiation in Q3 2026, expansion of its obesity portfolio around MBX 4291 and new candidates, and Phase 2 advancement of imapextide for post-bariatric hypoglycemia.
MBX Biosciences reported a Q1 2026 net loss of $23.5 million, similar to the prior year, as it advances multiple endocrine and metabolic drug programs. Research and development spending was $18.5 million, down mainly from lower MBX 4291 and imapextide costs, while general and administrative expenses rose to $8.8 million as the company scaled its public-company infrastructure.
MBX strengthened its balance sheet, ending March 31, 2026 with $440.0 million in cash, cash equivalents and marketable securities after a February 2026 at-the-market equity sale that raised $87.1 million in gross proceeds. Management believes this cash can fund operations into 2029 while it prepares a Phase 3 trial of canvuparatide for hypoparathyroidism, continues Phase 1 work on obesity candidate MBX 4291 and runs a Phase 2a study of imapextide for post-bariatric hypoglycemia.
MBX Biosciences reported a Q1 2026 net loss of $23.5 million, similar to the prior year, as it advances multiple endocrine and metabolic drug programs. Research and development spending was $18.5 million, down mainly from lower MBX 4291 and imapextide costs, while general and administrative expenses rose to $8.8 million as the company scaled its public-company infrastructure.
MBX strengthened its balance sheet, ending March 31, 2026 with $440.0 million in cash, cash equivalents and marketable securities after a February 2026 at-the-market equity sale that raised $87.1 million in gross proceeds. Management believes this cash can fund operations into 2029 while it prepares a Phase 3 trial of canvuparatide for hypoparathyroidism, continues Phase 1 work on obesity candidate MBX 4291 and runs a Phase 2a study of imapextide for post-bariatric hypoglycemia.
FMR LLC reported beneficial ownership of 2,936,684 shares of MBX Biosciences Inc. common stock, representing 6.2% of the class as reported on 03/31/2026. The filing lists sole dispositive power for 2,936,684 shares and includes Abigail P. Johnson as having shared dispositive power via FMR LLC.
MBX Biosciences director Steven L. Hoerter reported new equity awards and existing holdings. He received a grant of 11,938 shares of Common Stock as restricted stock units, which will vest in full on November 6, 2026, subject to his continued service.
He was also granted stock options covering 74,249 shares of Common Stock at an exercise price of $29.78 per share, expiring on May 1, 2036. This option grant vests 50% on the grant date and the remaining 50% in equal monthly installments over six months, conditioned on continued service. Separately, 20,000 Common Stock shares are held indirectly through the Steven L Hoerter Revocable Trust, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
MBX Rule 144 notice lists proposed and recent resale activity in Common shares. The excerpt shows a broker entry for Fidelity Brokerage Services LLC with 5000 shares and an amount field 159000.00 dated 05/01/2026. It also documents three reported sales by Richard B. Bartram: 10,000 shares on 03/16/2026 for $300,471.00, 1,061 shares on 03/25/2026 for $30,217.49, and 10,423 shares on 04/22/2026 for $341,377.72.
BlackRock, Inc. files an amendment reporting beneficial ownership of MBX BIOSCIENCES INC common stock. The amendment states BlackRock beneficially owns 2,287,497 shares, representing 4.8% of the class. It discloses 2,246,477 shares as sole voting power and 2,287,497 shares as sole dispositive power. The filing includes Exhibit 24 and Exhibit 99 and is signed by Spencer Fleming.
MBX reports proposed and recent insider sales of Common Stock via Form 144.
The filing lists 10,423 shares tied to a broker account on 04/22/2026 and notes recent dispositions: 10,000 shares sold on 03/16/2026 for $300,471.00 and 1,061 shares sold on 03/25/2026 for $30,217.49. Several option-originated lots with grant dates are shown for the 04/22/2026 sale.